Amgen(US:AMGN) Ge Long Hui·2025-11-05 05:52Core Viewpoint - Amgen (AMGN.US) reported strong third-quarter earnings, exceeding analyst expectations in both revenue and adjusted earnings per share, leading to a positive adjustment in its full-year guidance [1] Financial Performance - Amgen's third-quarter sales reached $9.56 billion, representing a 12% year-over-year increase, surpassing analyst expectations of $8.97 billion [1] - The adjusted earnings per share for the quarter were $5.64, also exceeding the forecast of $5.01 [1] Product Performance - The company's product portfolio demonstrated robust performance, with 16 products achieving double-digit sales growth during the quarter [1] Guidance Update - Amgen raised its full-year sales guidance from a range of $35 billion to $36 billion to a new range of $35.8 billion to $36.6 billion [1] - The adjusted earnings per share forecast was increased from $20.2 to $21.3 to a new range of $20.6 to $21.4, with analyst expectations at $21.04 [1]